Nvidia Invests in Another AI Pharmaceutical Startup, Vilya

In a move that further solidifies its commitment to the AI pharmaceutical space, Nvidia has participated in a $71 million Series A funding round for the startup Vilya. This latest investment comes as Nvidia's pace of investing in AI drug discovery companies appears to have slowed slightly compared to the frenetic activity seen in 2023.

Vilya, co-founded by renowned protein designer Dr. David Baker, is taking a novel approach to developing a new class of drug compounds known as macrocycles. These larger-than-small-molecule but smaller-than-antibody structures have shown promise for their ability to penetrate tissues and remain stable in the body. However, systematically generating these complex molecules has historically been a challenge.

Vilya claims to have developed proprietary computational methods that can design and predict the structures of a vast diversity of macrocyclic compounds. In a recent publication in the journal Science, the team reported designing 14.9 million candidate macrocycles, then synthesizing and testing a subset that demonstrated favorable properties like membrane permeability and protease stability.

The company's management team is also impressive, led by CEO Dr. Cyrus Harmon, a veteran of the drug discovery and computational biology fields. With this new funding, Vilya plans to advance its macrocycle drug candidates targeting proteins like HDAC6 and mPro into clinical development.

Nvidia's investment in Vilya is part of a broader strategy to position itself as a key platform provider for the AI-driven transformation of the pharmaceutical industry. Over the past year, the company's venture arm NVentures has backed 10 different AI drug discovery startups, indicating its ambitions to build an ecosystem around its AI technologies and hardware.

While the pace of Nvidia's AI pharma investments may have slowed slightly compared to the frenetic 2023 period, the company's interest in this space remains strong. The Vilya deal in particular highlights Nvidia's focus on supporting cutting-edge computational approaches that could unlock new frontiers in small molecule drug discovery.